Actinium Pharmaceuticals, Inc.
AMEX:ATNMBiotechnology
+$0.22 today
- Market cap
- $51.56M
- Beta
- 0.02
- P/E (TTM)
- 4.4
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.15M
ATNM Debt Repayment
Cash used to repay borrowings during the period.
Actinium Pharmaceuticals, Inc.AMEX: ATNM
Debt Repayment · Q2 FY2026 · quarter ended Jun 2026
Debt repayment dips below year-ago levels
Q2 FY2026 debt repayment of $2K (cash outflow) fell 33.3% year over year, behind the +11.1% change in trailing-twelve-month debt repayment. Sequentially, it fell 33.3% from the prior quarter. Over 3 fiscal years it compounded at -41.1% a year.
Context
- Debt repayment amounted to 11.1% of revenue in FY2025.
- Debt repayment grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -33.3% toward the trailing-twelve-month pace of +11.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- (10K) USD
- Year-over-year change
- -11.1%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10K) | -11.1% |
| FY2024 | 2024-12-31 | (9K) | -125.0% |
| FY2023 | 2023-12-31 | (4K) | +91.8% |
| FY2022 | 2022-12-31 | (49K) | +42.4% |
| FY2021 | 2021-12-31 | (85K) | — |
Debt Repayment vs competitors
How ATNM compares with its peers on the latest reported figures
- ATNM's LTM Jun 2026 debt repayment of $10K is the 2nd largest of the 5 companies compared; the peer median is $0.
- Its year-over-year change of +11.1% is the 2nd highest of 3, against a peer median of +99.6%.
- Debt repayment amounts to 0.0% of revenue for ATNM, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $25.17M | +299.1% | — | — | |
| LTM Jun 2026 | $10K | +11.1% | -41.1% | 0.0% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding ATNM) | $0 | +99.6% | — | 0.0% | |
Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Depreciation & Amortization | 524K | 699K | 790K | 811K | 821K |
| Deferred Income Tax | (1.55M) | 402K | 0 | 0 | 0 |
| Stock-Based Compensation | 1.69M | 2.8M | 3.84M | 5.29M | 9.19M |
| Change in Working Capital | 1.69M | 38.17M | (3.15M) | (932K) | (704K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.2M | 4.6M | (2.18M) | (387K) | (346K) |
| Other Working Capital | 495K | 33.57M | (972K) | (545K) | (358K) |
| Other Non-Cash Items | 1.55M | (402K) | 0 | 0 | 0 |
| Operating Cash Flow | (20.87M) | 8.64M | (47.34M) | (33.07M) | (24.58M) |
| Capital Expenditures | (133K) | (366K) | (153K) | (11K) | (104K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (133K) | (366K) | (153K) | (11K) | (104K) |
| Debt Repayment | (85K) | (49K) | (4K) | (9K) | (10K) |
| Common Stock Issued | 35.3M | 23.16M | 14.87M | 29.26M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (207K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6K | 0 | 0 | 75K | 0 |
| Financing Cash Flow | 35.22M | 23.11M | 14.87M | 29.32M | (217K) |
| Effect of Forex Changes | 0 | 0 | (11K) | 0 | 6K |
| Net Change in Cash | 14.22M | 31.39M | (32.63M) | (3.76M) | (24.9M) |
| Free Cash Flow | (21M) | 8.28M | (47.49M) | (33.08M) | (24.68M) |
Actinium Pharmaceuticals, Inc.
AMEX:ATNM
Intrinsic Alpha fair value
Locked
Current Price
$1.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.